Our data indicated that SEH treatment on CIS may be through the activation of PI3K/Akt//NF-κB signaling pathway to inhibit inflammatory factor releases and increase the antiapoptosis capacity. The gene discussed is NFKB1; the disease is in situ carcinoma.